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Abstract: The genus Yucca comprising of several species is dominant across the chaparrals, canyons and deserts of American 
South West and Mexico. This genus has long been a source of sustenance and drugs for the Native Americans. In the wake of  
revived interest in drug discovery from plant sources, this genus has been investigated and startling nutritive and therapeutic  
capacities have come forth. Apart from the functional food potential, antioxidant, antiinflammation, antiarthritic, anticancer,  
antidiabetic, antimicrobial, and hypocholesterolaemic properties have also been revealed. Steroidal saponins, resveratrol and  
yuccaols have been identified to be the active principles with myriad biological actions. To stimulate further research on this genus 
of multiple food and pharmaceutical uses, this updated review has been prepared with references extracted from MEDLINE database. 
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Introduction 
The genus Yucca belongs to Asparagaceae family and  
encompasses about 40–50 medicinally potent plants. These 
flowering plants generally thrive in arid parts of Southwestern 
US and Mexico, namely Mojave, Sonoran, Colorado and  
Chihuahuan Deserts, chaparrals of coastal California, sand 
dunes and Baja California. However, the species Yucca  
alofolia (Spanish bayonet) grows in Southeastern USA. Yucca 
whipplei (Chaparral yucca) is prevalent in the south California 
chaparral. Yucca brevifolia (Joshua tree) is the signature plant 
of Mojave Desert. Yucca schidigera (Mojave yucca) is  
prevalent across Mojave and Sonoran Deserts and regarded 
highly for its pharmaceutical values. Yucca elata (Soaptree 
yucca) is another distinct species in Sonoran and Chihuahua 
Deserts. Yucca elephantipes (Giant yucca) is often planted for 
landscape purpose in urban area. Figures of some important 
yucca species have been presented as Fig. 1. 
Apart from being a source of wide range of utilitarian  
products, this genus has found reputed place in folk medicine. 
These indigenous flowering succulent plants held  
ethno-botanical importance for Native Americans. The plant 
extracts were used to soothe joint pain, bleeding, urethral and 
prostate inflammations. They used the brewed leaves for 
common ailments as psoriasis, dandruff, hair loss and skin 
sores. Navajo Indians used it on sunburns and scratches. In 
northern New Mexico, healers used a tea from the leaves and 
roots to treat asthma and headache. The Catawba, Cherokee, 
Nanticoke and other Native American tribes used Yucca  
filamentosa as medicines and soap. The roots were crushed to 
make poultice for wound healing. Further, the roots were used 
to cure gonorrhoea and rheumatism. The Zuni tribe inhabiting 
the western New Mexico region used Yucca elata sap as hair 
growth stimulant. The infusion of the crushed leaves of Y. 
baccata has been used as an antiemetic and the fruits have 
been eaten raw as a laxative. Skin emollient, soporific agents 
and antidiabetic are other reported uses. The Chumash Indians 
consumed root, leaves and flower stalk. 
Now, this genus is receiving scientific validation and  
consumer acceptance. A wide array of yucca extract is  
marketed as capsules, beverages and herbal tea. ‘Now Foods’, 
markets a supplement rich in saponins for amelioration of joint 
pains. ‘Nature’s way’ manufactures a nutraceutical from Y. 
schidigera stalk. ‘Calivita’ sells a powder supplement under 
the brand name ‘Pure yucca’ to bolster metabolism and  
detoxification of gut. ‘Walmark’ trades Y. elata extract  
claiming its potency to boost metabolism, retard thrombosis 
and atherosclerosis risks, and ameliorate skin problems.  
‘Gluten-free remedies’ sells root extract of Y. schidigera to 
support normal flora of intestine and improve immune status. 
‘Health Aid’ markets Y. filamentosa root. High-grade Y.  
schidigera root extract has a considerable number of uses  
owing to the prolific plant saponins. Pharma giant ‘Swanson’ 
markets yucca capsules for amelioration of joint pain. 
 
1 Phytochemicals and Mechanisms of Action 
Virtually every part of yucca possesses bioactive compounds
viz. leaves, shoots, rhizomes, seed pods, flowers and bark. 
Several phytochemicals of therapeutic importance have been 
reported in recent times. Saponins are vital components of 
yucca with broad-spectrum biological properties. These  
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steroidal metabolites found in the shoots and rhizomes play 
key roles in food, cosmetics and pharmaceuticals. Saponins are 
surface-active sterol or triterpene glycosides with both polar 
and non-polar moieties. Their antibiotic, haemolytic and  
hypocholesterolaemic activity and ability to form stable foams 
in aqueous solution are well documented. The amphipathic 
nature renders them with surfactant property employable for 
enhancing penetration of proteins through cell membranes. 
The ability to reduce surface tensions of substances enables 
them to regulate blood clots, reduce thrombosis and eliminate 
heart attack risks. Further, they act as adjuvants for vaccines. 
Some saponins have been shown to enhance cytotoxicity of 
drugs against cancer. Steroidal saponins in yucca plant parts 
are precursors to cortisone, thus believed and to some extent, 
observed to provide relief from arthritis and rheumatism pain, 
as in case of Y. schidigera and Y. valida. Also, many  
polyphenolics including resveratrol and a number of other 
stilbenes have been reported. The phenolic compounds,  
yuccaols A, B, C, D and E have been isolated from yucca 
bark.1 Acid-hydrolysed fractions of yucca contain both  
furostanol and spirostanol aglycones. From the seeds of Y. 
glauca Nutt., sapogenins as sarsasapogenin, markogenin,  
tigogenin, neo-tigogenin, neo-gitogenin, hecogenin and  
gloriogenin have been isolated and identified. Ethanolic  
extract of Y. aloifolia yielded a new spirostanol glycoside.2 
The nuclear transcription factor NFB, stimulates the synthesis 
of inducible nitric oxide synthase (iNOS), which causes  
formation of the inflammatory agent nitric oxide. Yuccaols are 
inhibitors of the NFB, thus anti-inflammatory by nature. 
 
2 Food and Pharmaceutical Prospects 
A substantial number of published reports exist to lend  
credence to the functional food and pharmaceutical potentials 
of various yucca species. The biological roles of most-studied 
yucca species have been presented in Table 1. 
 
2.1 Food Additives 
Yucca extracts have acquired GRAS (Generally Recognized 
As Safe) status, thus approved for incorporation in foods. A 
saponin fraction was prepared from yucca for food use.3 The 
influence of water extract of Y. schidigera powder was  
evaluated on the foaming potential, structure of candy-foam 
and its stability during the shelf-life. The steroidal saponin 
containing extract exerted visible effect on structural attributes 
viz. dry matter content, hardness, density and porosity. The 
shelf-life was better than that of α-tocopherol, the freshness 
retained in a two month period observation.4 The foaming 
potential of the extract in beverages and soft drinks has been 
reviewed.5 
Mechanically sound and moisture-resistant films are sought 
in food industries for efficient packaging. The possibility of 
recruiting Y. schidigera-derived surfactant in manufacturing 
gelatine-based film was assessed.6 On extrusion, it demon-
strated good solubility to produce homogeneous films. Also, it 
showed better water barrier properties due to the characteristic 
hydrophobicity of the steroidal moiety of the saponin.  
However, the desired plasticizing effect was not obtained  




It was studied that the methanol extract of the bark of Y. 
periculosa F. Baker, the antioxidants stilbenes and  
resveratrols.7 It was observed that resveratrol and the phenolics
yuccaols A and C from the bark of Y. schidigera inhibits free 
radical generation in blood platelets and protect against  
cardiovascular diseases.8 The cisplastin-induced oxidative 
stress-counteracting effect of two phenolic compounds,  
stilbene and resveratrol sourced from Y. schidigera were  
assessed on human blood platelets and peripheral blood  
lymphocytes.9 Considerable reduction in oxidation of thiol 
groups of proteins was reported. The antioxidant and anti-
inflammatory properties of yuccaols (A, B, and C) isolated 
from Y. schidigera bark were validated further.10 LC/ESIMS 
(liquid chromatography coupled to electrospray mass  
spectrometry) qualitative and an LC/ESIMS/MS (liquid  
chromatography coupled to tandem electrospray mass  
spectrometry) quantitative proved to be the ideal strategy for 
separation and determination of yuccaols and gloriosaols. 
TEAC assay and ESIMS, NMR data confirmed that  
gloriosaols A–E extracted from Y. gloriosa has antioxidant 
activity.11,12 Y. schidigera and Y. gloriosa roots and barks  
contained these bioactive phenolics.13 The protective effects of 
Y. schidigera was assessed against oxidative damage induced 
by acute nitrite intoxication in murine models.14 The treatment 
with the extract was found to decrease methemoglobin, blood 
and tissue malondialdehyde, and tissue nitric oxide  
concentrations. Further, it increased the glutathione in blood 
and various tissues. Contrary to the control group, only  
moderate or mild haemorrhage and hyperaemia (abnormal 
amount of blood in the capillaries) were seen in kidneys of 
yucca-fed group. It was inferred that the extract can be used to 
lessen nitrite-induced oxidative damage and allied  
complications. The effect of dietary supplementation of Y. 
schidigera on lipid peroxidation was determined in  
arsenic-exposed mice. The group administered with different 
 
Figure 1.  Figures of some important yucca species 
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doses of yucca in diet and arsenic in drinking water for a  
period of 28 days resulted in reversal of the induced-oxidative 
stress and peroxidation. Also, the activities of antioxidant  
enzymes increased. Further, protection on focal gliosis (a  
localized accumulation of glial cells) and hyperaemia in brain, 




Yuccaols (A, B, and C) obtained from Y. schidigera bark 
were tested on cell proliferation, migration and platelet-
activating factor (PAF) biosynthesis. PAF, a potent mediator 
of inflammation, is known to promote angiogenesis and in 
vitro migration of endothelial cells and Kaposi's sarcoma cells. 
Yuccaols completely inhibited the VEGF-stimulated PAF  
biosynthesis and enhanced its degradation. Western blot  
analysis revealed that yuccaols reduces the VEGF-induced 
phosphorylation of p38 and p42/44, thus indicating a possible 
interference with the mechanism underlying the VEGF-
stimulated cell proliferation.10 The antitumor activity of Y. 
glauca against B16 melanoma has been reviewed.16 
 
2.4 Antiinflammamtory and Antiarthritic 
The anti-inflammatory property of Y. schidigera has been 
attributed to the resveratrol and yuccaol C content. It reduced 
the iNOS protein expression via the transcription factors 
NFB in E. coli LPS-activated macrophage cell line.1 It was 
showed that the saponin-containing fraction of the leaves of Y. 
schottii Engelm. exerts antiinflammatory properties against 
carrageenin-induced edema in rats.17 
 
2.5 Antidiabetic 
The effects of Y. schidigera, Quillaja saponaria and a mix-
ture of both plants were examined on streptozotocin-induced 
diabetic rats. After feeding for three weeks, the blood glucose 
level was found to be significantly lower. The insulin levels 
increased and the plasma cholesterol and triglyceride levels 
significantly decreased. Mononuclear leukocyte DNA damage, 
plasma malondialdehyde, and plasma protein carbonyl levels 
were found to be significantly lower.18 
 
2.6 Hypocholesterolaemic 
The effects of a blend of partially-purified Y. schidigera and 
Quillaja saponaria extracts on cholesterol levels in the human 
blood was studied. Taking 0.9 mg of the mixture (6:4, v:v) a 
day for a month resulted in decrease of total and LDL  
cholesterol levels in blood plasma of hyper-cholesterolaemic 
patients.25 
2.7 Antimicrobial 
Antiprotozoal role of saponins have been oft-proved. A  
saponin fraction from the stems of Y. schidigera exhibited 
inhibition against certain food-deteriorating, film-forming and 
dermatophytic yeasts and fungi.20 The antigiardial effect of 
oral intake of Y. schidigera powder was investigated by  
enumeration of gut trophozoites and faecal cysts in infected 
gerbils and lambs. The butanol extract (6.1 mg) or  
metronidazole (1 mg) taken once daily for three days reduced 
the number of trophozoites in the small intestine of infected  
gerbils. Oral dosing of 50 mg of the extract in eight doses over 
a period of 3 days reduced trophozoites in the duodenum and 
jejunum, and eliminated them from the ileum. 10 g powder/ 
day showed fewer cysts shedding. Further purification may 
exert more significant anti-giardial effects.21 The gastro-
intestinal tract responded to the anti-protozoal activity of  
saponins. The saponins of Y. schidigera proved as effective as 
the drug metronidazole in killing tropozoites of Giardia 
lamblia in the intestine. The mechanism of action was deduced 
to be due to binding of saponins with microbial membranes 
and causing pores in them.22 It was discovered that the leaf 
extract of Y. smalliana Fern. has also antimicrobial property.23 
The steroidal saponin, yuccalan demonstrated pronounced 
antifungal activity against Rhizoctonia solani and Fusarium 
oxysporum. Two spirostanol glycosides isolated from Y.  
elephantipes showed moderate inhibitory activity against  
Candida albicans and Cryptococcus neoformans.24 An anti-
mycotic substance, gloriofucin was prepared that contained 
spirostanol glycosides, extracted from the dried leaves of Y. 
gloriosa.25 
 
3 Enhancement of Bioactive Extraction 
Extraction of the bioactive constituents by traditional  
method as Soxhlet serves the purpose; however, for economical
efficiency advanced methods prove useful. Ultrasound-assisted 
extraction yielded better saponin content from ginseng  
compared to the conventional method. Microwave-assisted 
extraction using 80% methanol could dramatically reduce the 
extraction time of ginseng saponins from 12 h using  
conventional extraction methods to a few seconds.26 Ultrafil-
tration and sequential diafiltration can enhance the concentra-
tion of saponins of Y. schidigera from 9.3% to 17.2%.25 In an 
attempt to enhance metabolites sapogenins, Y. Schidigera  
rhizome organ culture was conducted.27 However, the quanti-
fication by HPLC did not show any significant improvement 
in addition of growth regulators. 
 
4 Discussion 
Ample literature exists on the therapeutic potency of  
Table 1. The functional compounds and biological roles of some medicinal Yucca species 
Plants Bioactive compound Therapeutic value Reference 
Yucca schidigera Saponin; Yuccaol C; Yuccaone A Animal health; Sugar-candy foam 
Anti-inflammatory; Antiproliferation; 
Hypocholesterolemic; Antidiabetic 
Holtshausen et al. 2009; Sucharzewska et al. 2003 
Marzocco et al. 2004; Balestrieri et al. 2006 
Kimet et al. 2003; Fidan and Dundar 2008 
Yucca gloriosa Gloriosaols A and B Antioxidant Montoro et al. 2010; Montoro et al. 2008 
Bassrello et al. 2007a; Bassrello et al. 2007b 
Yucca periculosa Resveratrol, Stilbene Antioxidant Torres et al. 2003 










Zhang et al. 2008 
Mouli et al. (2009) 
Jin et al. (2007) 
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steroidal saponins from varied plant sources. Steroidal  
saponins isolated from the roots of Asparagus acutifolius L. 
have showed antifungal activity against various Candida  
pathogens.28 The steroidal saponins from Agave utahensis 
have been reported to show strong cytotoxic activity against 
HL-60 human promyelocytic leukemia cells.29 Total steroidal 
saponins extracted from the rhizomes of Dioscorea  
zingiberensis exert healing effect on cardiovascular disease. It 
shows anti-thrombotic activity by prolonging the bleeding 
time and clotting time in a dose-dependent manner in mice.30 
Steroidal saponins isolated from the rhizomes of Paris  
polyphylla var. Yunnanensis demonstrated superior cytotoxic 
effects than cisplatin on human nasopharyngeal carcinoma 
epithelial cells. The saponins with diosgenin and  
tetrasaccharide moieties exerted the robust inhibitory effect 
mediated by apoptosis and cell cycle arrest.31 The saponins 
from various yucca species can also be explored for wide  
spectrum therapeutic potential. There exist sparse findings on 
the antitumor potential of Y. glauca Nutt., herpes simplex  
virus type 1 inhibition of yucca leaf protein, antimutagenicity 
of resveratrol from Y. schidigera against Salmonella  
typhimurium, anti-yeast action of spirostanol saponins from Y. 
schidigera. Research undertakings in these promising aspects 
must be revived. 
Going by the yucca-based dietary supplements being  
commercialized, health attributes of this genus are evident. 
The emerging clinical evidences of the therapeutic role calls 
for more research attention. Out of the 40–50 species only a 
few have been medicinally validated. The Y. brevifolia species, 
found abundantly in the Mojave National Preserve has been 
scarcely explored and can be an interesting subject for  
pharmaceutical discovery. Steroidal saponins have wide  
structural diversity and significant biological activities. Yucca 
saponins deserve more investigations in the interest of broader 
medicinal findings. Traditional knowledge of Native  
Americans could be consulted for research initiatives.  
Pharmacognosy will certainly be richer by contribution from 
this genus. However, the claims must be scientifically verified 
with more emphasis on human data. 
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